Report: State’s Life Science Industry Attracted $5B in 2021 Investments
Nearly $5.1 billion was invested in Washington state’s biotechnology and life science companies last year, according to Life Science Washington’s 2021 Washington State Investor Report.
The full report included early and later-stage VC, angel funding, mergers and acquisitions, initial public offerings and reverse mergers, accounting for 112 deals in the state.
Commenting on the results, Marc Cummings, president and CEO of Life Science Washington said: “It’s not easy to build a life science company and this report shows investors worldwide recognize the incredible innovation being developed by Washington companies — from emerging to established players and across all sectors of life sciences. These investors are placing bets on companies in an established hub with a deep history of global health innovation and a pioneering spirit that continues to create cutting-edge companies. This report also shows that investment is on a steady growth path, with our biotech companies leading the way.”